The EPO issued a patent publication for EP3550976A1, granting intellectual property protection to Salspera LLC for a cancer treatment composition. The invention combines a low-dose doxorubicin formulation (≤1.25 mg/kg) with attenuated Salmonella typhimurium engineered to express human interleukin-2. This combination therapy targets solid tumors and is classified under IPC codes A61P 35/00 and A61K 35/74.

Pharmaceutical companies and research institutions developing bacterial immunotherapy platforms or combination chemotherapies should review this patent to assess Freedom to Operate considerations. The designated states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR) indicate EU-wide plus extended European coverage. No immediate compliance action required beyond standard IP monitoring.